Results 1 to 10 of about 18,621 (199)

Delivery and Biosafety of Oncolytic Virotherapy [PDF]

open access: yesFrontiers in Oncology, 2020
In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy. Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self-replication and antitumor immunity responses, showing great potential for ...
Bin Tang
exaly   +5 more sources

Syncytia Formation in Oncolytic Virotherapy [PDF]

open access: yesMolecular Therapy - Oncolytics, 2019
Oncolytic virotherapy uses replication-competent virus as a means of treating cancer. Whereas this field has shown great promise as a viable treatment method, the limited spread of these viruses throughout the tumor microenvironment remains a major ...
Eric Bartee
exaly   +5 more sources

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

open access: yesPharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Andreas E Albers, Meiyu Fang, Xu Qian
exaly   +3 more sources

Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies [PDF]

open access: yesVirology Journal
Background and aim Oncolytic virotherapy is a novel therapeutic paradigm in oncology that uses viruses to selectively replicate within cancer cells, causing targeted tumor cell destruction with minimal toxicity to healthy tissues.
Omid Salahi Ardekani   +5 more
doaj   +2 more sources

Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends [PDF]

open access: yesCurrent Oncology
Oncolytic virotherapy has emerged as a promising and innovative approach to cancer treatment, leveraging viruses that selectively replicate in tumor cells and cause their destruction (oncolysis), while simultaneously stimulating anti-tumor immune ...
Cassandra Catacalos-Goad   +2 more
doaj   +2 more sources

Current strategies in engaging oncolytic viruses with antitumor immunity

open access: yesMolecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni   +2 more
doaj   +1 more source

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

open access: yesJournal of Hematology & Oncology, 2021
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far ...
Johannes P. W. Heidbuechel   +1 more
doaj   +1 more source

Lung cancer and oncolytic virotherapy——enemy's enemy

open access: yesTranslational Oncology, 2023
Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the
Zhang Li   +3 more
doaj   +1 more source

Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?

open access: yesBrain Sciences, 2021
Introduction: Melanoma brain metastases remain a devastating disease process with poor prognosis. Recently, there has been a surge in studies demonstrating the efficacy of oncolytic virotherapy for brain tumor treatment.
Sauson Soldozy   +12 more
doaj   +1 more source

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear.
Nader El-Sayes   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy